Mirvetuximab Soravtansine Granted Priority Review for Ovarian Cancer
Mirvetuximab soravtansine is an antibody-drug conjugate comprised of a FRα-binding antibody, a cleavable linker, and a potent tubulin-targeting agent.
Gynecologic Cancers
AYA Cancer Survivors Twice As Likely to Die From Second Cancer
The risk of dying from a subsequent primary cancer remained significantly elevated for 20 years or more for some patients.
Prevalence and Determinants of Late-Stage Disease at Presentation in Cervical Cancer
A meta-analysis sought to determine the rates of late-stage presentation among women with cervical cancer.
Trials Supporting Cancer Drug Approvals Lack Information on Gender
Of more than 100 studies used to support drug approvals, none reported information on the gender of participants.
Sexual Minority Status Linked to Lower Odds of Pap Screen
Odds of ever undergoing pap testing lower for non-Hispanic White and Hispanic SM participants versus non-Hispanic White heterosexuals.
Risk of Cancer-Specific Death May Remain Elevated for 30 Years
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
Risk of Breakthrough COVID-19 Varies by Cancer Type
The risk of breakthrough SARS-CoV-2 infections was highest for liver cancer and lowest for thyroid cancer.
Olaparib Alone, in Combination Does Not Improve PFS in Platinum-Sensitive Ovarian Cancer
Despite the lack of improvement in the overall cohort, olaparib monotherapy and olaparib-cediranib did exhibit activity in a subset of patients with a germline BRCA mutation.
Cancer Is Associated With Increased Kidney Failure Risk
The risk for kidney failure requiring renal replacement therapy varies by cancer type, with multiple myeloma associated with the highest risk.
Improving Timeliness of Goals of Care Conversations in Gynecologic Cancers
A cohort study of a pilot program assessed a template developed to guide care-related communications with patients with gynecologic cancers at high-risk of death.
- Loading...
Loading...
Next post in Gynecologic Cancer
Loading... 
Loading...